Tolga Tanguler - 24 Jun 2024 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Signature
By: Brett Budzinski, Attorney-in-Fact For: Tolga Tanguler
Issuer symbol
ALNY
Transactions as of
24 Jun 2024
Net transactions value
-$370,747
Form type
4
Filing time
26 Jun 2024, 16:26:27 UTC
Previous filing
05 Mar 2024
Next filing
13 Nov 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Award $0 +3,278 +33% $0.000000 13,265 24 Jun 2024 Direct F1
transaction ALNY Common Stock Sale $13,081 -59 -0.44% $221.71 13,206 25 Jun 2024 Direct F2, F3
transaction ALNY Common Stock Sale $2,914 -13 -0.1% $224.17 13,193 25 Jun 2024 Direct F2, F4
transaction ALNY Common Stock Sale $4,060 -18 -0.14% $225.55 13,175 25 Jun 2024 Direct F2, F5
transaction ALNY Common Stock Sale $7,712 -34 -0.26% $226.82 13,141 25 Jun 2024 Direct F2, F6
transaction ALNY Common Stock Sale $29,451 -129 -0.98% $228.30 13,012 25 Jun 2024 Direct F2, F7
transaction ALNY Common Stock Sale $60,930 -266 -2% $229.06 12,746 25 Jun 2024 Direct F2, F8
transaction ALNY Common Stock Sale $69,899 -304 -2.4% $229.93 12,442 25 Jun 2024 Direct F2, F9
transaction ALNY Common Stock Sale $22,927 -99 -0.8% $231.59 12,343 25 Jun 2024 Direct F2, F10
transaction ALNY Common Stock Sale $50,229 -216 -1.7% $232.54 12,127 25 Jun 2024 Direct F2, F11
transaction ALNY Common Stock Sale $26,856 -115 -0.95% $233.53 12,012 25 Jun 2024 Direct F2, F12
transaction ALNY Common Stock Sale $43,412 -185 -1.5% $234.66 11,827 25 Jun 2024 Direct F2, F13
transaction ALNY Common Stock Sale $39,277 -167 -1.4% $235.19 11,660 25 Jun 2024 Direct F2, F14
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 clinical study in ATTR amyloidosis with cardiomyopathy, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on June 24, 2024.
F2 Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
F3 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $221.37 to $222.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.92 to $224.43. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $224.99 to $225.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.45 to $227.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.72 to $228.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $228.75 to $229.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.76 to $230.70. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.92 to $231.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F11 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.97 to $232.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.00 to $234.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $234.06 to $235.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F14 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $235.10 to $235.73. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.